Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 2.33 MB, PDF document
Current psoriasis therapies have little-to-no effect on comorbidities such as obesity and chronic obstructive pulmonary disease (COPD). Apremilast, a phosphodiesterase 4 (PDE-4) inhibitor, is approved for moderate-to-severe psoriasis and considered a safe treatment option, that does not require laboratory monitoring. Nonetheless, lower efficacy compared with novel similar priced biologics, have led to modest use of apremilast in some countries. Roflumilast, a selective oral PDE-4 inhibitor, is approved for severe COPD in the US and EU. A common side effect of roflumilast therapy is weight loss, which has limited its use in COPD, where underweight is frequently observed.
Original language | English |
---|---|
Journal | British Journal of Dermatology |
Volume | 185 |
Issue number | 6 |
Pages (from-to) | 1251-1252 |
ISSN | 0366-077X |
DOIs | |
Publication status | Published - 2021 |
ID: 276230941